-+ 0.00%
-+ 0.00%
-+ 0.00%
Biomea Fusion Publishes Presentation on BMF-650 Phase 1 Obesity Study
Share
Listen to the news
Biomea Fusion Publishes Presentation on BMF-650 Phase 1 Obesity Study
  • Biomea Fusion published Phase 1 results for BMF-650, its oral GLP-1 receptor agonist for obesity.
  • Outpatients receiving a 300 mg daily target dose lost 3.2% of baseline weight by day 29, versus 0.1% with placebo.
  • A confined cohort lost 6.1% of baseline weight, with no meaningful difference versus placebo because of extensive food avoidance among placebo participants.
  • All treatment-emergent adverse events were mild to moderate; none led to study discontinuation or dosing changes.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Biomea Fusion Inc. published the original content used to generate this news brief on November 17, 2026, and is solely responsible for the information contained therein.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.
What's Trending